ABATACEPT: A NEW CHOICE FOR CHILDREN WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS

• Main Author: N. Ruperto
• Format: Article
• Language: English
• Published: "Paediatrician" Publishers LLC 2010-01-01
• Series: Voprosy Sovremennoj Pediatrii
• Online Access: http://vsp.spr-journal.ru:80/jour/article/view/602

<strong><em></em></strong><em>Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disorder in children. Children with polyarticular curse JIA, who do not respond to non-steroidal anti-inflammatory drugs and steroid injections, are treated with disease modyfing anti-rheumatic drugs with the first choice being methotrexate (MTX). For children not responding or intolerant to MTX, different therapeutic modalities with the so-called biologic agents, such as anti-tumor necrosis factor (TNF), are now available. However, a certain proportion of children with JIA, do not respond or are intolerant to anti-TNF therapy. This review summarises the available evidence related to the safety and efficacy profile of abatacept, a new selective co-stimulation modulator, for the treatment of polyarticular course JIA.</em><strong><em><br /><strong><em>Key words: children, juvenile idiopathic arthritis, juvenile rheumatoid arthritis, abatacept, inactive disease status, T-cell co-stimulation.</em></strong><br /></em></strong><em><span style="text-decoration: underline;"><em>(<em><em>Voprosy sovremennoi pediatrii — </em></em>Current Pediatrics. 2010;9(2):<em>32-39</em>)</em></span></em>